DaleJLangeMD

Neurology • New York, NY

Neuromuscular Medicine

President, Lange Neurology, PC 800 Fifth Ave (at 61st) Suite 203 New York, NY 10065 Clinical Professor of Neurology, Weill Cornell Medicine

Join to view full profile

Dr. Lange is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lange's full profile

Already have an account?

Office
800A Fifth Ave (at 61st)
Suite 203
New York, NY 10065

Summary

Dr. Dale Lange is a neurologist in New York, NY and is affiliated with New York-Presbyterian Hospital/Weill Cornell Medicine. He received his medical degree from New York Medical College and has been in practice for more than 35 year years. He specializes in neuromuscular medicine and is experienced in general neurology, ALS, CIDP, myasthenia gravis, polymyositis, muscular dystrophy, spinal cord disorders. muscular dystrophy and all nerve and muscle disorders. He has more than 100 publications and over 500 citings.

Education & Training

Tufts Medical CenterResidency, Neurology, 1979 - 1982
Albany Medical CenterInternship, Internal Medicine, 1978 - 1979
New York Medical CollegeClass of 1978

Certifications & Licensure

NY State Medical License 1982 - 2025
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2007-2014
Super Doctor SuperDoctors.com

Clinical Trials

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2009 Nov 01
Completed
Phase 1, Phase 2
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Completed
Phase 2
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Start of enrollment: 2015 Jun 01
Completed
Phase 2
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS Start of enrollment: 2020 May 28
Recruiting
Phase 2, Phase 3
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2021 Sep 02
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.
Steven Perrin, Shafeeq Ladha, Nicholas Maragakis, Michael H Rivner, Jonathan Katz
Plos Medicine. 2024-10-01
4 citations
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, pha...
Michael Benatar, Thomas Hansen, Dror Rom, Marie A Geist, Thomas Blaettler
The Lancet. Neurology. 2024-07-01
10 citations
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Merit Cudkowicz, Angela Genge, Nicholas J. Maragakis, Susanne Petri, Leonard H. van den Berg
The Lancet. Neurology. 2021-10-01

Press Mentions

What Can Cannabis Do for Patients with ALS?July 27th, 2019
Onetime Malaria Therapy Pyrimethamine Reduces Levels of ALS-Linked Protein, Study FindsJune 21st, 2017
Drug Found to Lower Levels of Biomarker Linked to ALSJune 12th, 2017
Join now to see all

Professional Memberships

American Academy of Neurology - AAN
Member